152 related articles for article (PubMed ID: 32700755)
1. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
3. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
Huang MB; Wu JY; Lillard J; Bond VC
Oncotarget; 2019 Sep; 10(52):5419-5438. PubMed ID: 31534628
[No Abstract] [Full Text] [Related]
4. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
7. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Starenki D; Sosonkina N; Hong SK; Lloyd RV; Park JI
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027376
[TBL] [Abstract][Full Text] [Related]
8. Mortalin (HSPA9) facilitates
Wu PK; Hong SK; Chen W; Becker AE; Gundry RL; Lin CW; Shao H; Gestwicki JE; Park JI
Sci Signal; 2020 Mar; 13(622):. PubMed ID: 32156782
[TBL] [Abstract][Full Text] [Related]
9. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
10. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
11. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
12. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
13. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.
Wu PK; Hong SK; Starenki D; Oshima K; Shao H; Gestwicki JE; Tsai S; Park JI
Oncogene; 2020 May; 39(21):4257-4270. PubMed ID: 32291414
[TBL] [Abstract][Full Text] [Related]
14. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
Fishelson Z; Kirschfink M
Front Immunol; 2019; 10():752. PubMed ID: 31024572
[TBL] [Abstract][Full Text] [Related]
15. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Sane S; Abdullah A; Nelson ME; Wang H; Chauhan SC; Newton SS; Rezvani K
Cell Stress Chaperones; 2016 Mar; 21(2):313-26. PubMed ID: 26634371
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.
Rozenberg P; Kocsis J; Saar M; Prohászka Z; Füst G; Fishelson Z
Int J Cancer; 2013 Jul; 133(2):514-8. PubMed ID: 23319326
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone.
Amick J; Schlanger SE; Wachnowsky C; Moseng MA; Emerson CC; Dare M; Luo WI; Ithychanda SS; Nix JC; Cowan JA; Page RC; Misra S
Protein Sci; 2014 Jun; 23(6):833-42. PubMed ID: 24687350
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.
Jin H; Ji M; Chen L; Liu Q; Che S; Xu M; Lin Z
J Exp Clin Cancer Res; 2016 Mar; 35():42. PubMed ID: 26955804
[TBL] [Abstract][Full Text] [Related]
19. Mortalin promotes breast cancer malignancy.
Zhang R; Meng Z; Wu X; Zhang M; Zhang S; Jin T
Exp Mol Pathol; 2021 Feb; 118():104593. PubMed ID: 33309613
[TBL] [Abstract][Full Text] [Related]
20. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]